abhishreshthaa
New member
DaVita, Inc. is one of the largest kidney care companies in the United States, with corprate headquarters in Denver, Colorado. Their offerings include in-center hemodialysis, peritoneal dialysis, home hemodialysis, vascular access management, chronic kidney disease education, and renal diet assistance.
Strengths
* Large market share position in some markets
* Focus on RX
* Management team capable of integrating Brooks-Eckerd acquisition
* Focus on customer support
* Strategic alliance with GNC
* Strategic Partnership with drugstore.com
* Online presence at riteaid.com
* Store cleanliness.
* Internal communications network.
Weaknesses
* Old store base
* Inconsistent store experience from West vs. East coast
* Declining market share
* Low sales productivity
* Less convenient real estate than Walgreens, CVS, WalMart
* Lacks PBM scale
* Poor private label equity
* Huge long term debt ($5.69 billion)
* Operating at a loss
* Low side of industry for Pharmacist Pay
Opportunities
* Aging population
* New generic drugs
* Expanding Drug Market
* Private label growth
* Leverage acquisition of Brooks-Eckerd
* Passage of Healthcare reform Bill (33 million more insured customers)
* diagnostic testing through DNA
Threats
* Integration
* Competitive pressure from pharmacies and other channels
* Eroding market share
* Higher mix of RX which has lower margins
* Political uncertianty
* Shortage of qualified Pharmacists
Strengths
* Large market share position in some markets
* Focus on RX
* Management team capable of integrating Brooks-Eckerd acquisition
* Focus on customer support
* Strategic alliance with GNC
* Strategic Partnership with drugstore.com
* Online presence at riteaid.com
* Store cleanliness.
* Internal communications network.
Weaknesses
* Old store base
* Inconsistent store experience from West vs. East coast
* Declining market share
* Low sales productivity
* Less convenient real estate than Walgreens, CVS, WalMart
* Lacks PBM scale
* Poor private label equity
* Huge long term debt ($5.69 billion)
* Operating at a loss
* Low side of industry for Pharmacist Pay
Opportunities
* Aging population
* New generic drugs
* Expanding Drug Market
* Private label growth
* Leverage acquisition of Brooks-Eckerd
* Passage of Healthcare reform Bill (33 million more insured customers)
* diagnostic testing through DNA
Threats
* Integration
* Competitive pressure from pharmacies and other channels
* Eroding market share
* Higher mix of RX which has lower margins
* Political uncertianty
* Shortage of qualified Pharmacists